Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:9/8/2008

REF="http://www.oncolyticsbiotech.com" target="_new">http://www.oncolyticsbiotech.com

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is among the nation's leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit our Web site at http://www.ctrc.uthscsa.edu.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
2. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
4. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
5. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
6. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
8. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... 28, 2014 The ability for organizations ... that will allow individuals to perform at the highest ... for employers looking to compete in this post–recession era. ... this trend, as the sector increasingly focuses on the ... which will have real results on the organization's development ...
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 2012 Codexis, Inc. (Nasdaq: CDXS ), ... of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced ... presenting at the Jefferies Global Clean Technology Conference, to ... 23, 2012 at 1:45 p.m. ET. A live webcast ...
... Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced that ... Conference. , Citi 2012 Global Health Care Conference ... February 29, 2012 , 9:00 a.m. ET ... presentation will be available at http://ir.avanir.com . ...
... Feb. 21, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: ... in the development, manufacturing, and marketing of branded generic ... will report its unaudited financial results for the fourth ... Wednesday, March 7, 2012, before the market opens in ...
Cached Biology Technology:Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012 2
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
(Date:8/29/2014)... Boulder, Colo., USA - The rise of the Tibetan ... on Earth -- is important for both its profound ... In this study published in GSA Bulletin , ... -- "clumped" isotope thermometry -- using modern and fossil ... Zhada basin in southwestern Tibet. , Views range ...
(Date:8/28/2014)... study reports that an expansion of marine protected areas ... ecological functions. According to investigators from the Wildlife ... fish have focused on saving the largest numbers of ... provide key and difficult-to-replace ecological functions. , ... by fish species that also are food for millions ...
Breaking Biology News(10 mins):Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... to a collection of test tubes in her Iowa State ... they were holding very weak coffee. That meant microorganisms ... converting sugars into hydrocarbons, said Jarboe, an Iowa State assistant ... the sugars in those test tubes were produced by the ...
... Heavy and prolonged snowfall can bring about unexpected conditions ... in the Arctic, according to experts. A new international ... helps plants to grow bigger, heavy and prolonged snow can, ... of killer fungal strains. The research results, published in ...
... studies in this special issue document the substantial and growing ... the burden of a chikungunya outbreak in India. Luiz ... country,s worsening trend; from 1999-2009, where cases rose at 6.2% ... Carmen Perez and co-workers, reporting on dengue vector control ...
Cached Biology News:Iowa State hybrid lab combines technologies to make biorenewable fuels and products 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 3Arctic snow harbors deadly assassin 2World Health Organization releases latest Dengue Bulletin 2World Health Organization releases latest Dengue Bulletin 3World Health Organization releases latest Dengue Bulletin 4World Health Organization releases latest Dengue Bulletin 5World Health Organization releases latest Dengue Bulletin 6World Health Organization releases latest Dengue Bulletin 7World Health Organization releases latest Dengue Bulletin 8
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
... Kit contains a green fluorescent-labeled inhibitor, FAM-VAD-FMK, ... valylalanylaspartic acid (VAD) fluoromethyl ketone (FMK), a ... added to a population of cells, the ... covalently binds to a reactive cysteine residue ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system, 220-240 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can generate high-density arrays ... slide or greater than 57,000 spots per ...
Biology Products: